Indivior PLC (NASDAQ:INDV) Shares Sold by Barclays PLC

Barclays PLC decreased its stake in shares of Indivior PLC (NASDAQ:INDV - Free Report) by 54.6% during the third quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 2,130,902 shares of the company's stock after selling 2,559,245 shares during the quarter. Barclays PLC owned about 1.55% of Indivior worth $20,776,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in INDV. Stifel Financial Corp acquired a new stake in shares of Indivior in the 3rd quarter worth $100,000. Melqart Asset Management UK Ltd purchased a new stake in shares of Indivior in the third quarter valued at about $132,000. Jane Street Group LLC acquired a new stake in Indivior during the third quarter worth about $180,000. Bank of New York Mellon Corp purchased a new position in Indivior during the second quarter worth about $188,000. Finally, VELA Investment Management LLC acquired a new position in Indivior in the 2nd quarter valued at about $235,000. Institutional investors and hedge funds own 60.33% of the company's stock.

Indivior Trading Up 0.6 %

INDV traded up $0.07 on Friday, hitting $11.57. The company had a trading volume of 1,121,030 shares, compared to its average volume of 559,361. The company's fifty day moving average price is $9.96 and its 200 day moving average price is $11.91. Indivior PLC has a 1 year low of $7.33 and a 1 year high of $23.22. The company has a current ratio of 0.83, a quick ratio of 0.65 and a debt-to-equity ratio of 23.50. The firm has a market cap of $1.60 billion, a P/E ratio of -289.25 and a beta of 0.75.

Indivior (NASDAQ:INDV - Get Free Report) last released its quarterly earnings results on Thursday, October 24th. The company reported $0.54 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.39 by $0.15. Indivior had a negative net margin of 0.17% and a negative return on equity of 351.08%. The business had revenue of $307.00 million for the quarter, compared to the consensus estimate of $302.25 million. As a group, equities analysts expect that Indivior PLC will post 1.68 earnings per share for the current year.

Analyst Ratings Changes

A number of analysts have recently issued reports on the stock. Craig Hallum cut their price target on shares of Indivior from $20.00 to $16.00 and set a "buy" rating for the company in a report on Friday, October 11th. Piper Sandler reiterated an "overweight" rating and issued a $16.00 price objective (up from $15.00) on shares of Indivior in a research report on Friday, October 25th.

Indivior Profile

Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders in the United States, the United Kingdom, and internationally. The company develops medicines to treat substance use disorders, serious mental illnesses, and opioid overdose.